人类肥胖中的肠道微生物组:综合性审查
Alejandro Borrego-Ruiz1, Juan J Borrego2
1Departamento de Psicología Social y de las Organizaciones, Universidad Nacional de Educación a Distancia (UNED), 28040 Madrid, Spain.
Biomedicines
|September 27, 2025
概括
肥胖影响全球数十亿人. 肠道微生物组在代谢健康中发挥着关键作用,与肥胖相关的变化以及潜在的治疗点,如益生菌和饮食.
科学领域:
- 微生物组研究 微生物组研究
- 代谢健康 代谢健康
- 肥胖研究 肥胖研究
背景情况:
- 超重和肥胖影响了数十亿人,预计这一数字将大幅增加.
- 肠道微生物组是宿主新陈代谢和能量平衡的关键调节者.
- 了解肠道微生物群对于开发新的肥胖治疗方法至关重要.
研究的目的:
- 审查肠道微生物在人类肥胖中的作用.
- 探索微生物组的变化,机制,饮食影响和治疗肥胖的治疗策略.
主要方法:
- 关于肠道微生物组和肥胖的综合文献综述.
- 微生物组变化,机制和饮食影响的分析.
- 基于微生物组的治疗方法的评估.
主要成果:
- 肥胖与肠道微生物多样性的减少和细菌类的改变有关.
- 肠道微生物组通过短链脂肪酸,炎症,基因调节和脂肪储存影响肥胖.
- 植物性饮食显示出保护作用,而基于微生物的疗法 (益生菌,FMT) 显示出治疗潜力.
结论:
- 肠道微生物组是导致肥胖和代谢障碍的重要因素.
- 饮食干预和基于微生物组的疗法为肥胖管理提供了有希望的途径.
- 微生物组研究的进步为个性化肥胖治疗铺平了道路.
相关概念视频
Obesity
1.1K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
247
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
247
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
169
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
169
What is Monogastric Digestion?
75.0K
The human body contains a monogastric digestive system. In a monogastric digestive system, the stomach only contains one chamber in which it digests food. Several other animal species also have monogastric digestive systems, including pigs, horses, dogs, and birds. This chapter, however, focuses on the human digestive system.
75.0K


